- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 | 113 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ("CERo" or the "Company"), an immunotherapy company developing the next generation of... ► Artikel lesen | |
| Mo | Cero Therapeutics-Aktie auf "Kaufen" hochgestuft dank Ansatz für solide Tumore | 2 | Investing.com Deutsch | ||
| Mo | Cero Therapeutics stock rating upgraded to Buy on solid tumor approach | 2 | Investing.com | ||
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.06. | CERo Therapeutics stock soars after FDA grants Orphan Drug Designation | 6 | Investing.com | ||
| 17.06. | CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) | 249 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen | |
| 13.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 | 3 | Seeking Alpha | ||
| 11.06. | CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split | 166 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen | |
| 06.06. | CERo Therapeutics gibt zusätzliche Serie-D-Aktien aus | 2 | Investing.com Deutsch | ||
| 06.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.06. | CERo Therapeutics issues additional Series D stock | 1 | Investing.com | ||
| 06.06. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing | 1 | GlobeNewswire (USA) | ||
| 02.06. | Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO) | 1 | Insider Monkey | ||
| 02.06. | CERo Therapeutics secures key patents for cancer therapy | 1 | Investing.com | ||
| 02.06. | CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236 | 1 | GlobeNewswire (USA) | ||
| 30.05. | CERo Therapeutics begins phase 1 trial for leukemia treatment | 3 | Investing.com | ||
| 30.05. | CERo Therapeutics startet Phase-1-Studie für Leukämie-Behandlung | 3 | Investing.com Deutsch | ||
| 30.05. | CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations | 316 | GlobeNewswire (Europe) | CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined... ► Artikel lesen | |
| 29.05. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | Maxim Group sets Cero Therapeutics stock with $3 target | 1 | Investing.com |
1 2 3 4 Weiter >>
74 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
CERO THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,590 Euro und damit -10,21 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.